



(12) Translation of  
European patent specification

(11) NO/EP 3068401 B1

NORWAY

(19) NO  
(51) Int Cl.  
*C07D 471/14 (2006.01)*  
*A61K 31/196 (2006.01)*  
*A61K 31/415 (2006.01)*  
*A61K 31/44 (2006.01)*  
*A61K 31/4412 (2006.01)*  
*A61K 31/4418 (2006.01)*  
*A61K 31/519 (2006.01)*  
*A61K 31/555 (2006.01)*  
*A61K 31/69 (2006.01)*  
*A61K 31/706 (2006.01)*  
*A61K 31/7068 (2006.01)*  
*A61K 45/06 (2006.01)*  
*A61P 35/00 (2006.01)*

**Norwegian Industrial Property Office**

---

(21)	Translation Published	2019.07.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.02.27
(86)	European Application Nr.	14861931.5
(86)	European Filing Date	2014.09.12
(87)	The European Application's Publication Date	2016.09.21
(30)	Priority	2013.11.15, US, 201361904718 P 2014.03.13, US, 201414208657 2014.07.25, US, 201414341392 2014.07.25, WO, PCT/US14/048241
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ME
(73)	Proprietor	Oncoceutics, Inc., 3675 Market Street Suite 200, Philadelphia, PA 19104, USA
(72)	Inventor	STOGNIEW, Martin, 1870 Ferguson Lane, Blue Bell, PA 19422, USA ALLEN, Joshua, E., 43 Chestnut St., Unit 311, New Haven, CT 06511, USA POTTORF, Richard S., 7550 Prairie View Dr., Indianapolis, IN 46526, USA NALLAGANCHU, Bhaskara Rao, 99 Nostrand Road, Hillsborough, NJ 08852, USA OLSON, Gary L., 1505 Coles Avenue, Mountainside, NJ 07092, USA
(74)	Agent or Attorney	Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017, 92665 ASNIÈRES-SUR-SEINE CEDEX, Frankrike


---

(54)	Title	<b>7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, SALTS THEREOF AND METHODS OF USE</b>
(56)	References Cited:	<p>WO-A1-2015/153468 DE-A1- 2 150 062 US-B2- 7 635 690 US-A1- 2013 209 518 US-A1- 2013 172 314 US-A1- 2004 067 953 US-A1- 2007 149 571 US-A1- 2008 221 135 US-A1- 2010 266 540 US-A1- 2012 128 732 US-A1- 2012 276 088 WO 2016/123571, 4 August 2016 (2016-08-04), NICHOLAS T. JACOB ET AL: "Pharmacophore Reassignment for Induction of the Immunosurveillance Cytokine TRAIL", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 53, no. 26, 23 June 2014 (2014-06-23) , pages 6628-6631, XP055259380, DE ISSN: 1433-7851, DOI: 10.1002/anie.201402133 ALLEN, JOSHUA E. ET AL: "Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects", SCIENCE TRANSLATIONAL MEDICINE , 5(171), 171RA17, 14 PP. CODEN: STMCBQ; ISSN: 1946-6242, 6 February 2013 (2013-02-06), XP002761508, DOI: 10.1126/SCITRANSLMED.3004828 WO 2017/132661, 3 August 2017 (2017-08-03),</p>

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**Patentkrav**

- 1.** Forbindelse med en formel (10)



5

(10)

eller et salt derav.

hvor R<sub>1</sub> er CH<sub>2</sub>Ph, og hvor R<sub>2</sub> er CH<sub>2</sub>-(2,4-di F-Ph).

- 10    **2.** Forbindelsen ifølge krav 1, hvorfor bindelsen er et hydroklorid-di-salt.
- 15    **3.** Farmasøytisk sammensetning omfattende forbindelsen ifølge krav 1 eller 2 og et farmasøytisk akseptabelt bæremiddel.
- 20    **4.** Den farmasøytiske sammensetningen ifølge krav 3, videre omfattende et antikreftmiddel i tillegg.
- 5.** Forbindelsen ifølge krav 1 eller 2, eller den farmasøytiske forbindelsen ifølge krav 3 eller 4, til anvendelse som et medikament.
- 6.** Forbindelsen ifølge krav 1 eller 2, eller den farmasøytiske forbindelsen ifølge krav 3 eller 4, til anvendelse ved behandling av kreft.